• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

老年膀胱癌的个体化治疗：一例具有乳头状特征的高级别尿路上皮癌个性化管理的病例报告

Tailoring treatment for elderly bladder cancer: a case report of personalized management of high-grade urothelial carcinoma with papillary features.

作者信息

Nikolaidis Christos G, Gyriki Despoina, Anitsakis Charalambos, Stavropoulou Elisavet

机构信息

Internal Medicine Department, Vostaneio-General Hospital of Mytilene, Mytilene, Greece.

Master Program in "Food, Nutrition and Microbiome", Laboratory of Hygiene and Environmental Protection, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

出版信息

Front Oncol. 2024 Aug 6;14:1434795. doi: 10.3389/fonc.2024.1434795. eCollection 2024.

DOI:10.3389/fonc.2024.1434795
PMID:39165685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11333216/
Abstract

This case study presents the diagnostic and therapeutic course of a 72-year-old male patient with a history of high-grade urothelial carcinoma with papillary features. The report outlines the patient's initial presentation, the intervention strategies employed, including transurethral resection and intravesical Bacillus Calmette-Guérin (BCG) therapy, the subsequent complications and clinical decisions following the intense symptoms post-treatment. The study highlights the challenges in managing bladder cancer in elderly patients, considering the tumor's characteristics, treatment responses, and the patient's quality of life.

摘要

本病例研究介绍了一名72岁男性患者的诊断和治疗过程，该患者有高级别乳头状尿路上皮癌病史。报告概述了患者的初始症状、所采用的干预策略，包括经尿道切除术和膀胱内卡介苗（BCG）治疗、治疗后出现强烈症状后的后续并发症及临床决策。该研究强调了在老年患者中管理膀胱癌时所面临的挑战，需考虑肿瘤特征、治疗反应及患者生活质量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e1f/11333216/370fcc1a4b65/fonc-14-1434795-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e1f/11333216/5a2d86f7a4a5/fonc-14-1434795-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e1f/11333216/370fcc1a4b65/fonc-14-1434795-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e1f/11333216/5a2d86f7a4a5/fonc-14-1434795-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e1f/11333216/370fcc1a4b65/fonc-14-1434795-g002.jpg

相似文献

1
Tailoring treatment for elderly bladder cancer: a case report of personalized management of high-grade urothelial carcinoma with papillary features.老年膀胱癌的个体化治疗：一例具有乳头状特征的高级别尿路上皮癌个性化管理的病例报告
Front Oncol. 2024 Aug 6;14:1434795. doi: 10.3389/fonc.2024.1434795. eCollection 2024.
2
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌（TaT1 和原位癌）指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
3
Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.卡介苗诱导治疗后首次评估时膀胱癌的乳头状复发：对临床试验设计的启示
Eur Urol. 2016 Nov;70(5):778-785. doi: 10.1016/j.eururo.2016.02.031. Epub 2016 Feb 24.
4
Poncet's disease after the intravesical instillation of Bacillus Calmette-Guérin (BCG): a case report.膀胱内灌注卡介苗（BCG）后发生的庞塞病：一例报告。
BMC Res Notes. 2017 Aug 18;10(1):416. doi: 10.1186/s13104-017-2606-9.
5
Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.卡介苗治疗失败的患者可能是非肌层浸润性膀胱癌，原因可能是泌尿科医生未能检测到上尿路和尿道的尿路上皮癌。
Eur Urol. 2014 Apr;65(4):825-31. doi: 10.1016/j.eururo.2013.09.049. Epub 2013 Oct 9.
6
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).欧洲泌尿外科学会非肌层浸润性膀胱癌（Ta、T1和原位癌）指南
Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10.
7
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南：非肌层浸润性膀胱尿路上皮癌：2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
8
Renal Tuberculosis Following Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer.膀胱癌行膀胱内卡介苗（BCG）免疫治疗后并发肾结核。
Med Arch. 2020 Apr;74(2):146-150. doi: 10.5455/medarh.2020.74.146-150.
9
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.EAU 指南：非肌层浸润性膀胱尿路上皮癌：2013 年更新版。
Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Epub 2013 Jun 12.
10
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.EORTC 泌尿生殖系统肿瘤组随机 3 期研究 30911 的长期疗效结果，比较表柔比星、卡介苗和卡介苗联合异烟肼膀胱内灌注治疗中高危期 TaT1 尿路上皮膀胱癌患者的疗效。
Eur Urol. 2010 May;57(5):766-73. doi: 10.1016/j.eururo.2009.12.024. Epub 2009 Dec 18.

引用本文的文献

1
Urothelial carcinoma arising in orthotopic ileal neobladder reconstruction: A case report.原位回肠新膀胱重建术后发生的尿路上皮癌：一例报告。
World J Clin Cases. 2025 Sep 16;13(26):104876. doi: 10.12998/wjcc.v13.i26.104876.

本文引用的文献

1
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward.纳多法基因菲拉地诺韦的演变：综述与未来之路。
Bladder Cancer. 2024 Jun 18;10(2):105-112. doi: 10.3233/BLC-230083. eCollection 2024.
2
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.非肌层浸润性膀胱癌的诊断与治疗：美国泌尿外科学会/泌尿外科学会指南：2024年修订版
J Urol. 2024 Apr;211(4):533-538. doi: 10.1097/JU.0000000000003846. Epub 2024 Jan 24.
3
ERAS® protocol improves survival after radical cystectomy: A single-center cohort study.
加速康复外科（ERAS®）方案可改善根治性膀胱切除术患者的生存：单中心队列研究。
Medicine (Baltimore). 2022 Sep 2;101(35):e30258. doi: 10.1097/MD.0000000000030258.
4
BCG in Bladder Cancer Immunotherapy.卡介苗在膀胱癌免疫治疗中的应用
Cancers (Basel). 2022 Jun 23;14(13):3073. doi: 10.3390/cancers14133073.
5
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.膀胱癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Mar;33(3):244-258. doi: 10.1016/j.annonc.2021.11.012. Epub 2021 Nov 30.
6
Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.回复：帕博利珠单抗单药治疗对卡介苗无反应的高危非肌层浸润性膀胱癌（KEYNOTE-057）：一项开放标签、单臂、多中心2期研究。
Eur Urol. 2021 Nov;80(5):671. doi: 10.1016/j.eururo.2021.07.020. Epub 2021 Aug 5.
7
Non-muscle-invasive bladder cancer: An overview of potential new treatment options.非肌肉浸润性膀胱癌：潜在新治疗选择的概述。
Urol Oncol. 2021 Oct;39(10):642-663. doi: 10.1016/j.urolonc.2021.05.015. Epub 2021 Jun 22.
8
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.帕博利珠单抗单药治疗卡介苗（BCG）无应答的高风险非肌肉浸润性膀胱癌（KEYNOTE-057）：一项开放标签、单臂、多中心、2 期研究。
Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26.
9
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
10
Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC).非肌肉浸润性膀胱癌（NMIBC）中卡介苗失败的当前治疗方法。
Actas Urol Esp (Engl Ed). 2021 Mar;45(2):93-102. doi: 10.1016/j.acuro.2020.08.003. Epub 2020 Oct 2.